# A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

> **NCT01958671** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 461 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Ertugliflozin 10 mg
- **DRUG:** Placebo to Ertugliflozin
- **DRUG:** Metformin
- **DRUG:** Placebo to Metformin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01958671
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-09
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-07-28
- **Target enrollment:** 461 (ACTUAL)
- **Last updated:** 2017-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958671, "A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01958671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*